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Abstract
Background: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a rare but severe and sometimes
fatal condition associated with exposure to medications; sulfamethoxazole is among the most common causes. We
sought to address the safety of acetazolamide, a chemically related compound, in patients with prior SJS/TEN and
glaucoma. A retrospective case series is described of patients at the Massachusetts Eye and Ear Infirmary who
underwent keratoprosthesis surgery for corneal blindness from SJS/TEN, and later required oral acetazolamide for
elevated intraocular pressure.
Findings: Over the last 10 years, 17 patients with SJS/TEN received a Boston keratoprosthesis. Of these, 11
developed elevated intraocular pressure that required administration of oral acetazolamide. One of 11 developed a
mild allergic reaction, but no patient experienced a recurrence of SJS/TEN or any severe adverse reaction.
Conclusion: Although an increase in the rate of recurrent SJS/TEN due to oral acetazolamide would not necessarily
be apparent after treating only 11 patients, in our series, acetazolamide administration was well tolerated without
serious sequela.
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Findings
Background
Stevens Johnson syndrome and toxic epidermal necroly-
sis (SJS/TEN), two ends of a spectrum of severe adverse
drug reactions affecting the skin and mucosa, typically
result from hypersensitivity to a medication and manifest
by acute sloughing of skin and mucous membranes. Sec-
ondary complications can be similar to burn patients
with extensive loss of skin and mucosa, fever, hepatic,
renal, and/or gastrointestinal involvement, sepsis, and
death. Medications implicated in SJS/TEN include most
commonly sulfonamides, anti-seizure medications, peni-
cillins, and allopurinol, with onset of symptoms occur-
ring within 1–8 weeks of drug administration [1-3]. SJS/
TEN has an incidence of 1 to 6 cases per million person-
years, and carries an overall mortality up to 15 % for SJS
to 50 % for TEN. Ocular involvement during the acute
phase occurs in up to 50-69 % of patients with SJS/TEN
[4]. For survivors, severe dry eye, cicatricial ocular sur-
face damage, and corneal blindness are feared outcomes.
In one study, the prevalence of ocular complications of SJS
was 20 % at 3 months following onset of SJS/TEN [5]. In
our experience, however, patients with chronic ocular
complications of SJS/TEN tend to worsen with time.
In patients with loss of conjunctival fornices, keratiniz-
ing dry eye, and subsequent corneal blindness, the Bos-
ton keratoprosthesis type II, a collar button device of
polymethylmethacrylate and titanium, is implanted to
provide visual recovery [6]. However, postoperative glau-
coma is common, even when a aqueous drainage device
is implanted [7]. In Boston keratoprosthesis type II im-
plantation, the eyelids are closed surgically around the
prosthesis, as shown in Figure 1, after which, topical
glaucoma drops have limited usefulness. Tube shunt fail-
ure after keratoprosthesis type II is common, and neces-
sitates revision of the shunt or implantation of a second
tube. Opening the fused eyelids for shunt revision or re-
placement, or for transcleral cyclophotocoagulation [7]
may interfere with anatomic stability of the keratoprosth-
esis. Acetazolamide is a sulfonamide chemically distinct
from sulfonamide antibiotics such as sulfamethoxazole.
Use of oral acetazolamide or its sister drug methazola-
mide may be the only option in patients after Boston
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prosthesis, a different technique for restoration of end-
stage cicatricial corneal blindness [8]. However, concerns
over use of acetazolamide causing a second episode of
SJS/TEN in keratoprosthesis patients have been raised
[9], even when the drug initially associated with the
patient’s SJS/TEN is not of the same chemical class.
Herein, we review the current literature pertaining to
the use of sulfa-derivative medications in patients with a
history of SJS/TEN, and present a series of patients at
the Massachusetts Eye and Ear Infirmary in whom aceta-
zolamide was used to treat intraocular pressure rises
after implantation of a Boston keratoprosthesis.
Methods
We performed a literature search using the search terms:
Stevens-Johnson syndrome, toxic epidermal necrolysis,
sulfa, Diamox, acetazolamide, allergy, and cross-reactiv-
ity. No articles were found that specifically addressed the
safety of administration of sulfonamide nonantibiotics to
patients with a history of SJS/TEN. With approval by the
Human Studies Committee of the Massachusetts Eye
and Ear Infirmary, we then performed a chart review of
all patients with SJS/TEN who underwent Boston kerato-
prosthesis surgery from January 1, 2000 until December
31, 2010.
Results
We identified 17 such patients; eleven (Table 1) were
found to have received oral acetazolamide to reduce
intraocular pressure at some point following their kera-
toprosthesis surgery. One patient had a type I kerato-
prosthesis (without eyelid surgery) but all others had a
type II keratoprosthesis (eyelids surgically fused closed).
Of the 11 patients who received oral acetazolamide, only
one patient experienced an adverse reaction (warmth and
pruritis); this occurred after 10 days of close monitoring.
The affected patient never developed urticaria or dyspnea.
Acetazolamide was stopped immediately upon development
of symptoms, and no further adverse events occurred. It
should be noted that the SJS/TEN in this patient was attrib-
uted to ibuprofen. The patient did not have a known allergy
to acetazolamide, but had been told by her internist to avoid
“sulfa” drugs due to their strong association with SJS/TEN.
None of the patients in our series who were given acetazo-
lamide reported sulfa as a cause of their SJS/TEN, but two
reported the drug as an allergy. Interestingly, penicillin was
thought to be the trigger for the SJS/TEN in both patients
with sulfa allergy. Penicillin allergy seems to confer a heigh-
tened sensitivity to many other classes of medications [10].
Of the six patients who did not require oral acetazolamide,
i nt h r e eas u l f ad r u gc a u s e dt h e i rS J S / T E N ,i nt w oi to c -
curred after treatment with penicillin, and in one patient
the SJS/TEN was of unknown etiology (data not shown).
All patients treated with oral acetazolamide demonstrated
helpful reductions in intraocular pressure. In summary,
acetazolamide was used in 11 SJS/TEN patients after kera-
toprosthesis, for a total of 16.3 person-years, with only one
mild adverse reaction, and no reactivation of SJS/TEN.
Discussion
SJS/TEN manifests clinically as mucocutaneous erythma
and blistering, and leads to variable degrees of full thick-
ness necrosis of skin and mucosae. The best available evi-
dence suggests that SJS/TEN is drug metabolite specific,
cytotoxic T cell-driven, and perforin/granzyme B triggered
[3,11-18]. Specific HLA types associate with an increased
risk of SJS/TEN to particular drugs [19-21]. In addition,
fas and fas ligand have been implicated in the disorder,
and may contribute to the characteristic expansion of
keratinocyte apoptosis as the condition progresses [1,3,22].
Given the very real risk of death and the significant mor-
bidity associated with SJS/TEN, and the disorder’ss t r o n g
association with sulfonamides [2], controversy regarding
the safety of acetazolamide in SJS/TEN is understand-
able. Furthermore, the rarity of SJS/TEN means that
even a substantial increase in SJS/TEN incidence due to
acetazolamide could be missed by individual physicians.
Although many different medications have been
associated with SJS/TEN, the drug most commonly
Figure 1 Clinical appearance of the Boston type II keratoprosthesis in the left eye of a patient with history of toxic epidermal
necrolysis. Note the tight apposition between the eyelid skin and the keratoprosthesis stem (arrow).
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component of a commonly used combination antibiotic
also containing trimethoprim. Re-administration of
trimethoprim-sulfamethoxazole to a patient who pre-
viously developed SJS/TEN due to the same drug can
cause recurrent SJS/TEN [23]. Numerous sources now
support an absence of cross-reactivity between aceta-
zolamide, a non-sulfonylarylamine, in patients with al-
lergy to sulfamethoxazole [10,14,24,25].
Despite a common SO2NH2 group, there are two crit-
ical structural differences which distinguish sulfonamide
antimicrobials such as sulfamethoxazole and sulfona-
mide nonantimicrobials such as acetazolamide; and
these differences distinguish the drugs chemically and
immunologically. Allergic reactions to sulfamethoxazole
represent IgE-mediated immediate hypersensitivity reac-
tions to the N1 heterocyclic ring, a structural component
absent in acetazolamide [12,15]. Metabolite formation and
subsequent specific cytotoxic Tcell responses is stereospe-
cific to the N4 amino nitrogen of sulfamethoxazole, also
not found in acetazolamide [12,15].
Caution is indicated when prescribing any drug to a pa-
tient with prior SJS/TEN. However, in such patients aceta-
zolamide should not be feared more than other drugs,
even when the inciting agent for the original SJS/TEN was
sulfamethoxazole. An interesting comparison may be
made to celecoxib, another sulfonamide nonantibiotic [26].
Between January and June of 1999, 7 million prescriptions
were written but only two possible cases of SJS/TEN were
reported. If the risk of celecoxib causing SJS/TEN was
similar to sulfamethoxazole, 7 million prescriptions would
result in 30 to 70 cases of SJS/TEN [2,26]. This additional
evidence supports a lack of cross reactivity induced by the
two classes of sulfonamides.
In such a rare disorder as SJS/TEN, randomized clinical
trials cannot be performed. Our retrospective case series
includes too few patients to determine that acetazolamide
is safe in patients with prior SJS/TEN. However, it is re-
assuring that we were able to safely administer acetazola-
mide to patients with a history of SJS/TEN, even the two
patients reporting a “sulfa” allergy. We have not adminis-
tered acetazolamide to any patient with sulfamethoxazole
induced SJS/TEN. However, our case series is generally
supportive of the use of acetazolamide in patients with a
history of SJS/TEN, a population thought to have a higher
incidence of drug-induced hypersensitivity.
Conclusions
In conclusion, individuals with a history of SJS/TEN
should be approached conservatively when it comes to ad-
ministration of any medication. Safety measures such as
skin testing, low test-dose administration of medication or-
ally while under direct supervision, and HLA testing [21]
may increase confidence in specific cases. In the setting of
keratoprosthesis, oral acetazolamide may be the only
medication short of glaucoma surgery which can lower
intraocular pressure. We currently use oral acetazolamide
in patients with SJS/TEN after implantation of the Boston
Table 1 Demographics of treated patients
Pt. no. Age at
onset of SJS/TEN
(years)
Inciting agent
for SJS/TEN
Self-reported
drug allergies
Time after surgery
when
acetazolamide
started (months)
Presence of
glaucoma
drainage tube
pre-acetazolamide
Time on
acetazolamide
(months)
Adverse
reactions to
acetazolamide
1 43 ibuprofen NSAID 1 day Y 10 days Warmth and
pruritis
2* 48 sulindac NSAID 24 N 1 N
3 40 allopurinol,
erythromycin,
colchicine
same 9 Y 9 N
4 50 Not known terfenadine 0 N 31 N
5 3 PCN PCN, sulfa,
erythromycin
5 N 1.5 N
6 36 Not known PCN, cefazolin,
erythromycin
2 Y 24 N
7 54 bupropion,
atenolol
same 13 Y 30 N
8 25 Not known NKDA 7 Y 24 N
9 13 aspirin,
ibuprofen
same 0.75 Y 1.5 N
10 Not known Not known PCN, codeine Not known Not known 9 N
11 27 PCN PCN, sulfa 2 Y 64 N
*This patient received a Boston keratoprosthesis type I.
PCN: penicillin; NSAID: nonsteroidal anti-inflammatory drug.
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vated intraocular pressure in the early postoperative
period, and chronically in select patients with glaucoma
shunt failure.
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